What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?

Seminars in Diagnostic Pathology

Volumn 32, Issue 6, 2015, Pages 469-479

  Pelosi, Giuseppe ^a,b   Fabbri, Alessandra ^a   Cossa, Mara ^a   Sonzogni, Angelica ^a   Valeri, Barbara ^a   Righi, Luisella ^c   Papotti, Mauro ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Carcinoid; Diagnosis; Grading; Immunohistochemistry; Ki 67; Large cell; Molecular pathology; Neuroendocrine; Predictive; Prognosis; Small cell; Survival; Tumor

Indexed keywords

KI 67 ANTIGEN;

ARTICLE; CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; DISEASE CLASSIFICATION; HUMAN; LUNG NEUROENDOCRINE TUMOR; LUNG TUMOR; NEUROENDOCRINE TUMOR; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; BIOPSY; CELL PROLIFERATION; CHEMISTRY; CLASSIFICATION; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; NEUROSECRETORY CELL; NOMENCLATURE; PATHOLOGY;

BIOPSY; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; NEOPLASM GRADING; NEUROENDOCRINE CELLS; NEUROENDOCRINE TUMORS; PREDICTIVE VALUE OF TESTS; TERMINOLOGY AS TOPIC;

EID: 84951860738     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2015.10.009     Document Type: Article

References (113)

1. Travis W., Brambilla E., Burke A., Marx A., Nicholson A. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 2015, IARC Press, Lyon. 4th ed.
2. Travis W., Colby T., Corrin B., Shimosato Y., Brambilla E. Hystological Typing of Lung and Pleural Tumours 1999, Springer Verlag, Berlin, Heidelberg, New York.
3. Travis W., Brambilla E., Muller-Hermelink H., Harris C. Tumours of the Lung, Pleura, Thymus and Heart 2004, IARC Press, Lyon.
4. Caplin M.E., Baudin E., Ferolla P., et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 2015, 26:1604-1620.
5. Nicholson S.A., Beasley M.B., Brambilla E., et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002, 26:1184-1197.
6. Travis W.D., Gal A.A., Colby T.V., Klimstra D.S., Falk R., Koss M.N. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998, 29:272-279.
7. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22:934-944.
8. Kunz P.L. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 2015, 33:1855-1863.
9. Godwin J.D., Brown C.C. Comparative epidemiology of carcinoid and oat-cell tumors of the lung. Cancer 1977, 40:1671-1673.
10. Asamura H., Kameya T., Matsuno Y., et al. Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 2006, 24:70-76.
11. Moran C.A., Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. Hematol Oncol Clin North Am 2007, 21:395-407. [vii].
12. Pelosi G., Hiroshima K., Mino-Kenudson M. Controversial issues and new discoveries in lung neuroendocrine tumors. Diagn Histopathol 2014, 20:392-397.
13. Rindi G., Klersy C., Inzani F., et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 2014, 21:1-16.
14. Travis W.D. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin 2014, 24:257-266.
15. den Bakker M.A., Thunnissen F.B. Neuroendocrine tumours-challenges in the diagnosis and classification of pulmonary neuroendocrine tumours. J Clin Pathol 2013, 66:862-869.
16. den Bakker M.A., Willemsen S., Grunberg K., et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology 2010, 56:356-363.
17. Travis W.D., Brambilla E., Nicholson A.G., et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015, 10:1243-1260.
18. Filosso P.L., Guerrera F., Evangelista A., et al. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Groupdagger. Eur J Cardiothorac Surg 2015, 48:441-447.
19. Lou F., Sarkaria I., Pietanza C., et al. Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg 2013, 96:1156-1162.
20. Mete O., Asa S.L. Precursor lesions of endocrine system neoplasms. Pathology 2013, 45:316-330.
21. Capella C., Heitz P.U., Hofler H., Solcia E., Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995, 425:547-560.
22. Franks T.J., Galvin J.R. Lung tumors with neuroendocrine morphology: essential radiologic and pathologic features. Arch Pathol Lab Med 2008, 132:1055-1061.
23. Marchevsky A.M., Gal A.A., Shah S., Koss M.N. Morphometry confirms the presence of considerable nuclear size overlap between small cells and large cells in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 2001, 116:466-472.
24. Nicholson A.G., Gonzalez D., Shah P., et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010, 5:436-441.
25. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010, 134:1628-1638.
26. Fernandez-Cuesta L., Peifer M., Lu X., et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun 2014, 5:3518.
27. Iwakawa R., Takenaka M., Kohno T., et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer 2013, 52:802-816.
28. Peifer M., Fernandez-Cuesta L., Sos M.L., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012, 44:1104-1110.
29. Pelosi G., Papotti M., Rindi G., Scarpa A. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol 2014, 25:151-164.
30. Rudin C.M., Durinck S., Stawiski E.W., et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012, 44:1111-1116.
31. Swarts D.R., Claessen S.M., Jonkers Y.M., et al. Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcome. Am J Pathol 2011, 179:1129-1137.
32. Swarts D.R., Ramaekers F.C., Speel E.J. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta 2012, 1826:255-271.
33. Seidel D., Zander T., Heukamp L.C., et al. Clinical Lung Cancer Genome Project and Network Genomic Medicine, A genomics-based classification of human lung tumors. Sci Transl Med 2013, 5:209ra153.
34. Toffalorio F., Belloni E., Barberis M., et al. Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids. Br J Cancer 2014, 110:1244-1249.
35. Swarts D.R., Henfling M.E., Van Neste L., et al. CD44 and OTP are strong prognostic markers for pulmonary carcinoids. Clin Cancer Res 2013, 19:2197-2207.
36. Jones M.H., Virtanen C., Honjoh D., et al. Two prognostically significant subtypes of high-grade lung neuroendocrine tumours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles. Lancet 2004, 363:775-781.
37. Pelosi G., Pasini F., Fraggetta F., et al. Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids. Lung Cancer 2003, 42:203-213.
38. Azzopardi J. Oat-cell carcinoma of the bronchus. J Path Bact 1959, 78:513-519.
39. Barnard W. The nature of the oat-celled sarcoma of the mediastinum. J Path Bact 1926, 29:241-244.
40. Arrigoni M.G., Woolner L.B., Bernatz P.E. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg 1972, 64:413-421.
41. Hamperl H. Ueber gutartige Bronchilatumoren (Cylindrome und Carcinoide). Virchows Arch (Pathol Anat) 1937, 300:46.
42. Modlin I.M., Shapiro M.D., Kidd M. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol 2004, 35:1440-1451.
43. Oberndorfer S. Karzinoide Tumoren des Dünndarms. Frankfurter Zeischrift Pathol 1907, 1:426-432.
44. Travis W.D., Linnoila R.I., Tsokos M.G., et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol 1991, 15:529-553.
45. Gould V.E., Linnoila R.I., Memoli V.A., Warren W.H. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest 1983, 49:519-537.
46. Cerilli L.A., Ritter J.H., Mills S.E., Wick M.R. Neuroendocsrine neoplasms of the lung. Am J Clin Pathol 2001, 116. S65-96.
47. Moran C.A., Suster S., Coppola D., Wick M.R. Neuroendocrine carcinomas of the lung: a critical analysis. Am J Clin Pathol 2009, 131:206-221.
48. Wick M.R. Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol 2000, 113:331-335.
49. Paladugu R.R., Benfield J.R., Pak H.Y., Ross R.K., Teplitz R.L. Bronchopulmonary Kulchitzky cell carcinomas. A new classification scheme for typical and atypical carcinoids. Cancer 1985, 55:1303-1311.
50. Axiotis C. The neuroendocrine lung. Endocrine Pathology 2002, 261-296. Churchill Livingstone, New York, Edinburgh. V. Li Volsi, S. Asa (Eds.).
51. Huang Q., Muzitansky A., Mark E.J. Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. Arch Pathol Lab Med 2002, 126:545-553.
52. Capella C., Heitz P.U., Hofler H., Solcia E., Kloppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994, 55(suppl 3):11-23.
53. Solcia E., Klöppel G., Sobin L. Histological Typing of Endocrine Tumours 2000, Springer, Heidelberg. 2nd ed.
54. Zahel T., Krysa S., Herpel E., et al. Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Arch 2012, 460:299-308.
55. Swarts D.R., van Suylen R.J., den Bakker M.A., et al. Interobserver variability for the WHO classification of pulmonary carcinoids. Am J Surg Pathol 2014, 38:1429-1436.
56. Warth A., Fink L., Fisseler-Eckhoff A., et al. Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Arch 2013, 462:507-513.
57. Ha S.Y., Han J., Kim W.S., Suh B.S., Roh M.S. Interobserver variability in diagnosing high-grade neuroendocrine carcinoma of the lung and comparing it with the morphometric analysis. Korean J Pathol 2012, 46:42-47.
58. Iyoda A., Hiroshima K., Nakatani Y., Fujisawa T. Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 2007, 84:702-707.
59. Righi L., Volante M., Rapa I., Scagliotti G.V., Papotti M. Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Arch 2007, 451(suppl 1):S51-S59.
60. Beasley M.B., Thunnissen F.B., Brambilla E., et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000, 31:1255-1265.
61. Righi L., Volante M., Rapa I., et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocr Relat Cancer 2010, 17:977-987.
62. Righi L., Volante M., Tavaglione V., et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 "clinically aggressive" cases. Ann Oncol 2010, 21:548-555.
63. Righi L., Graziano P., Fornari A., et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011, 117:3416-3423.
64. Tsuta K., Liu D.C., Kalhor N., Wistuba, Moran C.A. Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 2011, 136:252-259.
65. Papotti M., Sapino A., Righi L., Chiappone S., Bussolati G. 34betaE12 cytokeratin immunodetection in the differential diagnosis of neuroendocrine carcinomas of the breast. Appl Immunohistochem Mol Morphol 2001, 9:229-233.
66. Sturm N., Lantuejoul S., Laverriere M.H., et al. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001, 32:918-925.
67. Pelosi G., Rossi G., Cavazza A., et al. DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol 2013, 21:229-239.
68. Pelosi G., Pasini F., Olsen Stenholm C., et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. J Pathol 2002, 198:100-109.
69. Pelosi G., Rindi G., Travis W.D., Papotti M. Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 2014, 9:273-284.
70. Tang L.H., Gonen M., Hedvat C., Modlin I.M., Klimstra D.S. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 2012, 36:1761-1770.
71. Pelosi G., Rodriguez J., Viale G., Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol 2005, 29:179-187.
72. Wang H., Iyoda A., Roh M.S., et al. WHO histologic classification is an independent predictor of prognosis in lung neuroendocrine (NE) tumors but Ki-67 proliferation rate is not (abstract #1952). Mod Pathol 2013, 26:469A.
73. Aslan D.L., Gulbahce H.E., Pambuccian S.E., Manivel J.C., Jessurun J. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol 2005, 123:874-878.
74. Lin O., Olgac S., Green I., Zakowski M.F., Klimstra D.S. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol 2003, 120:209-216.
75. Walts A.E., Ines D., Marchevsky A.M. Limited role of Ki-67 proliferative index in predicting overall short-term survival in patients with typical and atypical pulmonary carcinoid tumors. Mod Pathol 2012, 25:1258-1264.
76. Costes V., Marty-Ane C., Picot M.C., et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol 1995, 26:740-745.
77. Grimaldi F., Muser D., Beltrami C.A., et al. Partitioning of bronchopulmonary carcinoids in two different prognostic categories by ki-67 score. Front Endocrinol (Lausanne) 2011, 2:20(1-6).
78. Rugge M., Fassan M., Clemente R., et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res 2008, 14:149-154.
79. Pelosi G., Bresaola E., Bogina G., et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996, 27:1124-1134.
80. Rindi G., Falconi M., Klersy C., et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012, 104:764-777.
81. Bastrurk O., Yang Z., Tang L., et al. Increased (>20%) Ki-67 proliferation index in morphologically well differentaited pancreatic neuroendocrine tumors (PanNETs) correlates with decreased overall survival (abstract #1761). Mod Pathol 2013, 26:423A.
82. Basturk O., Tang L., Hruban R.H., et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 2014, 38:437-447.
83. Swarts D.R., Scarpa A., Corbo V., et al. MEN1 Gene mutation and reduced expression are associated with poor prognosis in pulmonary carcinoids. J Clin Endocrinol Metab 2014, 99:E374-E378.
84. Klimstra D.S., Modlin I.R., Adsay N.V., et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010, 34:300-313.
85. Klimstra D.S., Modlin I.R., Coppola D., Lloyd R.V., Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010, 39:707-712.
86. Yang Z., Tang L.H., Klimstra D.S. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. Semin Diagn Pathol 2013, 30:186-196.
87. Gridelli C., Rossi A., Airoma G., et al. Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev 2013, 39:466-472.
88. Fasano M., Della Corte C.M., Papaccio F., Ciardiello F., Morgillo F. Pulmonary large-cell neuroendocrine carcinoma: from epidemiology to therapy. J Thorac Oncol 2015, 10:1133-1141.
89. Ceppi P., Volante M., Ferrero A., et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008, 14:1059-1064.
90. Skov B.G., Holm B., Erreboe A., Skov T., Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 2010, 5:453-459.
91. Jakobsen J.N., Sorensen J.B. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer 2013, 79:1-7.
92. Abrahams E. Right drug-right patient-right time: personalized medicine coalition. Clin Transl Sci 2008, 1:11-12.
93. Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008, 44:30-38.
94. Monica V., Scagliotti G.V., Ceppi P., et al. Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung. Clin Cancer Res 2009, 15:7547-7552.
95. Caplin M.E., Pavel M., Cwikla J.B., et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014, 371:224-233.
96. Wolin E.M. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointest Cancer Res 2012, 5:161-168.
97. Zatelli M.C., Maffei P., Piccin D., et al. Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab 2005, 90:2104-2109.
98. Volante M., Brizzi M.P., Faggiano A., et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007, 20:1172-1182.
99. Pelosi G., Volante M., Papotti M., Sonzogni A., Masullo M., Viale G. Peptide receptors in neuroendocrine tumors of the lung as potential tools for radionuclide diagnosis and therapy. Q J Nucl Med Mol Imaging 2006, 50:272-287.
100. Zatelli M.C., Minoia M., Martini C., et al. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids. Endocr Relat Cancer 2010, 17:719-729.
101. Gagliano T., Bellio M., Gentilin E., et al. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer 2013, 20:463-475.
102. Righi L., Volante M., Rapa I., Vatrano S., Pelosi G., Papotti M. Therapeutic biomarkers in lung neuroendocrine neoplasia. Endocr Pathol 2014, 25:371-377.
103. Rossi G., Cavazza A., Graziano P., Papotti M. mTOR/p70S6K in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Am J Respir Crit Care Med 2012, 185(341):341-342. [author reply].
104. Song J., Li M., Tretiakova M., Salgia R., Cagle P.T., Husain A.N. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med 2010, 134:1702-1705.
105. Voortman J., Harada T., Chang R.P., et al. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des 2013, 19:833-840.
106. Pelosi G., Scarpa A., Veronesi G., et al. A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. Virchows Arch 2005, 447:969-977.
107. Casali C., Stefani A., Rossi G., et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 2004, 77:247-252. [discussion 252-243].
108. Rossi G., Cavazza A., Marchioni A., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23:8774-8785.
109. Iyoda A., Travis W.D., Sarkaria I.S., et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med 2011, 2:1041-1045.
110. Nomura M., Fukuda T., Fujii K., et al. Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. An FFPE proteomic study. J Clin Bioinforma 2011, 1:23.
111. Swarts D.R., Van Neste L., Henfling M.E., et al. An exploration of pathways involved in lung carcinoid progression using gene expression profiling. Carcinogenesis 2013, 34:2726-2737.
112. George J., Lim J.S., Jang S.J., et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015, 524:47-53.
113. Fernandez-Cuesta L, Peifer M, Lu X, et al. Cross-entity mutation analysis of lung neuroendocrine tumors sheds light into their molecular origin and identifies new therapeutic targets (abstract #1531). AACR Annual Meeting of the American Association of Cancer Research. San Diego, CA; 2014.